🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
4.550
+0.180 (4.12%)
At close: Nov 18, 2026, 4:00 PM EST
4.540
-0.010 (-0.22%)
After-hours: Nov 18, 2026, 7:57 PM EST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

Three U.S. product decisions were expected in December, while 2027 growth is anticipated from Humira, Stelara, Simponi and new launches. High-dose Eylea filings and launches provide longer-term catalysts.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

All right. Good afternoon. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech and spec pharma analyst here at Jefferies. I have the wonderful pleasure of having Alvotech here with us. We have Róbert Wessman, Chairman of Alvotech, as well as Balaji Prasad, Chief Strategy Officer. Welcome, guys.

Róbert Wessman
Chairman, Alvotech

Yeah, thank you so much.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

So before we kind of dive into the portfolio, maybe just remind us of Alvotech's progress this year, and just generally speaking, I know you guys won't give financial guidance for 2027.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Just also how to think about 2027 as well.

Róbert Wessman
Chairman, Alvotech

No, I think the company is definitely at a big inflection point. We have invested over $2 billion into the company since 2013. We have one of the broadest portfolio in the industry, over 30 products in the pipeline. We have launched five of them into Europe, two into U.S., and we are having three launches, we assume, end of this year into U.S., one being biosimilar to Simponi, where we hopefully will be either first or one of two. The same product we launched in Europe, and we are the only one on the market there. I would say, I mean, we landed last year with a $600 million top line. The company is less than three years commercial into U.S. So, we are on a good track.

We expect the growth next year will be driven by both a strong order book for our first two products, biosimilar to Stelara and Humira, which we launched both in U.S. and the rest of the world, plus very good traction in Europe with Simponi, and of course, launches into U.S. So, I would say we are super excited about the year 2027, and guidance most likely will be given with the year-end result, if you will.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. Maybe comment a little bit thematically on biosimilars in general, right? I feel like it makes total sense to have those products on the market, but just talk about how the U.S. and ex-U.S. are different, and what have you learned during the first few years of some of these biosimilars launching?

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, it was interesting when we started; of course, back in time, there was no regulation around how to develop biosimilars. So, 2013, when we started to build the company, that was done on back of lack of kind of guidance how to develop the products. Europe and the U.S. is different. I mean, 65% of biologic sales happens in U.S., and which is pretty amazing. We have around 20%, 25% of the biologic sales in Europe. Europe is, of course, a little bit different market based on different countries. I mean, some markets are purely tenders, other are still partly retail, others are countrywide tenders, others are regional or local tenders. So, in Europe, it's important to have a strong partner. We have partnered with the likes of STADA and Advanz, which have access to all the different channels.

In U.S., I mean, you have either buy and bill or you have pharmacy benefit products. Our upcoming launches are mostly geared to buy and bill, which tends to be a little bit less tension when it comes to pricing, if you will. There, of course, we have been mostly working with Teva, which have access to all those different channels, and very interesting to see Teva being able to continue to capture markets here, especially in biosimilar to Humira.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. When you look out over the next 10, 15 years, there is going to be so many different biologics that are going to go off patent. Given that you guys have a pretty broad portfolio and pipeline, I guess, how do you pick and choose which products that you guys would focus on? What are the different factors that weigh on your decision to pursue one over another?

Róbert Wessman
Chairman, Alvotech

Yeah. No, it is a good point. I mean, we look, of course, at complexity, if you will, and that can be both in the IP and technically, and more complex is something we like, because simply to add any value, we need to be first to market or in the first wave. If you would pick a blockbuster, which is pretty straightforward, you would usually see 10 players in that. Once we pick the products, it can go into different directions. It is like a few examples; when we picked Humira, halfway into it, we heard that AbbVie was developing high dose. We canceled our development of low dose, and I think we were already spending $40 million into it and started with high dose.

We are the first to launch high dose interchangeable with citrate-free with amazing auto-injectors. We were the one litigated the most and got into the market. I mean, we are also seeing the brands like, likes of Eylea, low dose. We are seeing fast conversion into the high dose now. Obviously, it is much less injection in the eye, so it is for the benefit of patients. We have seen over 50% conversion in Europe, 35% I believe in U.S. The OcuClick, which is a device of Regeneron, most likely will enhance that much more. So, when we learned that, we started development of the high dose even before the brand launches. We did six different formulation, expecting, speculating how Regeneron would develop that product. Once it came out, we had the perfect match. So, we kind of had the formulation at the same time as the brand launched.

Entyvio, where we are also first, and we have submitted the high dose now globally, except in U.S., which comes a bit later, first company. On the Entyvio, we were the first to submit that. We have both the vial, we have also the prefilled and auto-injector. Very interesting. I mean, it was too small to pick at the beginning when we looked at it. When we learned that Takeda was going to do head-to-head to Humira, we were convinced that they would be able to show stronger efficacy, at least in some indication, which was the fact they ended up being stronger in the UC indication, and the product multiplied by that. Because we started earlier, assuming that this would be the case, we are the first. We start with a product we believe in.

Maybe the product is very small, can grow because of a new indication or different reason. Technically complex, IP landscape might be complex. Then, we chase the brand wherever the brand goes. What we start with might not necessarily be what we end with. That's kind of how we choose. But we have been consistent with spending over $200 million in R&D every year.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay, got it. So, it's a combination of complexity of the molecule, the market, IP, timing, all those things. I think you really need to be dynamic and adapt to—

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

—how things are changing.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Having said that, would love to hear your views on just the latest FDA guidance around biosimilar development, and how does that impact Alvotech and maybe the industry?

Róbert Wessman
Chairman, Alvotech

No, it is another one, which is a very good question. I mean, just to say it, because it is just us here in the room, we did spend $350 million on Humira biosimilar to develop it. We did interchangeability study, and around Humira, we have amazing auto-injector, which is working very well for us when it comes to marketing. I mean, since then, a lot have changed. Of course, the patient phase III study is out. We expected that, so kind of two years ago, we started to invest more in preclinical, if you will, and process development. It was kind of a good win for us that those changes came in good time, both for Europe and U.S. And we managed to kind of establish our portfolio because we had kind of almost two years with the expectation that this would happen.

It has helped us a lot. The cost for development, as I said, is from $50 million, can go higher, of course, with oncology if you have a full patient study. But the price have come a lot down, and it is more clear how to move forward.

Balaji Prasad
Chief Strategy Officer, Alvotech

It also definitely helped us, Dennis, target some of the products which were on the, let us say, the sub-$2 billion scale. So, it made that accessible too, bring down the cost of development. So, you will see that there are quite a few in our portfolio, which also plays to our strength of little complexity, and so there is limited competition in that space too.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. Perfect. Maybe if we turn to your own business right now. Remind us of the third quarter and just some of the dynamics there around guidance and the timing of orders and all that stuff.

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, we are basically expecting approval for those three products in December. So, we have been, of course, busy both with a very strong order book, but also on preparing for some of those. We were at a slowdown in the production till mid-year, if you will, and the third quarter basically reflects that a bit. Late end of June, we were at a full capacity, and we are running at full capacity. So, with start to finish for many of our products is up to six months from start until released into market. So, that's why we are seeing a very strong fourth quarter, and the fourth quarter will be by far the best quarter in the company history, if you will.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Right. And for the people who aren't necessarily aware, you had some issues around your Iceland facility. You've remediated all that. Everything's okay. And that's really important because, like you said, we're going into three biosimilar PDUFAs in December.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Right.

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, the company got a CRL for our three BLAs. The facility has been, of course, producing for U.S. since 2024 mid. And we have, as you said, remediated that. We have had an inspection since then, and we have gotten two approvals, one with the double expansion of our drug substance manufacturing, and then we got approval for our process change with Humira, which allows us to get double the drug substance out of each batch. So, yes. So, we have cleared that, and we are very confident on approval 4th of December.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. I think that's really important because you mentioned you had some approvals over the summer around the manufacturing coming out of the facility.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Can you comment a little bit around just the dialogue with the FDA on those three applications over the last couple of weeks? How have they been, and just overall, how are you feeling going into that?

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, before we resubmitted, the FDA had already gone through our BLAs without any observation. So, the BLAs are clear. We were waiting for clearing the facility, and there is basically no dialogue with FDA as we stand. We are just waiting for the approval. We got two approvals, as I said, in October, and these came a week before, actually, the PDUFA date, and they were waiting for the same remediation, if you will. So, that's why, I mean, if FDA wanted to come yet again for an inspection, they would have done that before approving those two.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Okay, you feel good going to—

Róbert Wessman
Chairman, Alvotech

Absolutely. I mean, we are two weeks from the PDUFA date now.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Maybe if we can focus on one of the biosimilars, which is Simponi.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Right? That is a $2 billion product globally, probably $1 billion in the U.S. There is a competitor out there who is tied up with litigation, but you guys also have a pretty important legal catalyst coming up on the preliminary injunction. So—

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Maybe just talk a little bit about your confidence going into that you would have a positive decision, meaning the judge would deny J&J's request for a PI.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Just how to think about that, given that that's a fairly big opportunity.

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, the product is globally north of $3 billion. There are only two players which have gotten approval for it, so we do not expect to see anyone anytime soon. We came into the market in Europe alongside the other player. That player stopped fairly short, got a big issue in Europe, had to withdraw, and most likely will be out for a while. They had already submitted also in U.S. On our PI case, which we expect to be ruled early December, most likely before PDUFA date, J&J inserted only one patent, and that patent is basically not even relevant to our production process. We are using totally different production process. We are using perfusion. So, we were kind of surprised that J&J wanted to go this route. I mean, J&J has its own antitrust issue and have been sued for that in U.S.

So, we were kind of surprised that they took one of their patents which they bought. That patent, by the way, does not apply to Simponi. It's a G&L patent, and as far as I know, Simponi is not even using that process themselves. I mean, you can hear that we are very confident that this will be turned down.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. And to be clear, it's the 986 patent. It's a manufacturing patent.

Róbert Wessman
Chairman, Alvotech

Exactly.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

But you're saying J&J doesn't even use it.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

I don't think you guys use it.

Róbert Wessman
Chairman, Alvotech

We do not use it. We have a perfusion process, so we are not using it.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. When we think about how judges think about PIs, there is usually four pillars, right?

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

There is the merits of the case.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Irreparable harm.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Public interest, and then balance of equities, right?

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

I feel like out of those four, merits is probably one of the most important ones.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Right?

Róbert Wessman
Chairman, Alvotech

Very important to us, and I think if you do not use the process yourself, it is very difficult to show harm even.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Right. Okay. That's a great point.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay, so assuming that you guys do get a favorable decision on the PI, how should we think about the U.S. launch? Could it be a relatively near-term event in 2027 from your partner, Teva? I know they've commented that they're operationally ready to launch in 2027. We'd love to hear.

Róbert Wessman
Chairman, Alvotech

Yeah, I mean, because it's a partnership, it's very difficult to say anything else than Teva has already said. I mean, I would just underline that we are ready. We are super excited. It's a unique opportunity. I think the U.S. is at least $1.5 billion, I believe. I mean, it's an amazing opportunity for both Teva and us, and as Teva stated, they will be ready, then we are ready, and it's exciting times ahead.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. And maybe just real quick, just from a logistics perspective, when the judge issues a PI, regardless of the outcome, both parties or either party would probably appeal, and that appeal would probably take a few months, like—

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

— do you have a comment on how long do you think that appeals process can take? Do we feel like we need to get an appeals decision before your partner launches in the U.S.? Is there any kind of color that you can provide there?

Róbert Wessman
Chairman, Alvotech

No, I mean, we have said our case is very strong. I would be extremely surprised if anything else will be done than denied. As Teva said, we are ready, and you know what that means.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Maybe if we can shift over to Eylea High Dose.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

That's also a really interesting opportunity. Maybe just talk broadly about that opportunity and then where we are around the clinical timelines, the regulatory timelines, et cetera.

Róbert Wessman
Chairman, Alvotech

No, I think High Dose Eylea is super interesting. One classic case, as I mentioned, we basically developed the product before it was launched by Regeneron. In U.S., U.S. FDA wanted additional patient study, clinical, if you will. We are just ongoing with that. We expect to file very early 2028, with approval very early 2029. In Europe and rest of the world, we have submitted. We have announced that. That will be approved next year. We basically filed a PGR against Regeneron because of the patents which they are using and applying. We strongly feel that those are subject to prior art and obviousness, and we believe we have a very strong case there.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay. Maybe just explain to people what a PGR is, post-grant review. What does that mean, and what are you trying to achieve with that? Because when you talk with Regeneron, they are saying, we have IP that goes all the way to 2039.

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

How do you think about that?

Róbert Wessman
Chairman, Alvotech

Yeah, it is a forum where you can basically invalidate patents. We both have invalidation, but we also have non-infringement position towards the product. Basically, this will be then We filed this. This will be then heard and ruled on. We feel very strongly about that we can invalidate because the judge will simply look at the merit of the case. I know that Regeneron made a few statements which are kind of very interesting, and I am happy to answer those if you want to ask. But overall, assuming in the worst case that we would not win, then we still have in U.S. till 2029 early to basically go to court. But if you look at low dose, Amgen, [Pavblu], they were the first one there. I think with a limited discounts, they managed on a full-year basis to generate a billion-dollar sales.

Today, high dose is most likely between $2.5 billion-$3 billion and will be growing. The device which Regeneron has, we basically have that. We have spent a couple of years developing that, $20 million. We will come with not only the high dose, we will come with the same device. All in all, for us, this is super exciting opportunity, if you will, both outside U.S. and in U.S. Again, we are the first to submit filing outside U.S. in the world, and approval expected next year.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

In the U.S., how would you characterize the timing of the Eylea High Dose biosimilar launch?

Róbert Wessman
Chairman, Alvotech

It very much depends on the PGR case. If we invalidate the patents, which we hope and expect we do, we will open up what we need to open up. It will just make our life easier. I think the timelines on approval, you will see us there in U.S.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Got it.

Róbert Wessman
Chairman, Alvotech

On the market.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay.

Balaji Prasad
Chief Strategy Officer, Alvotech

I think what we could probably also add, Dennis, is that we do expect to be the first to file in the U.S. too. Similar to what we have done now with the first filing that you have seen a month ago. We'll expect to be the first to file in the U.S. also, and that obviously puts us on a path to get the first approval also.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Sure. That's in 2028?

Balaji Prasad
Chief Strategy Officer, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Okay, perfect. No more legal questions from me. Maybe in the last couple minutes, we can kind of talk a little bit about your base business, right?

Róbert Wessman
Chairman, Alvotech

Yeah.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

You have some Simlandi and some Selarsdi, but there are so many moving parts both in the U.S. and OUS and all these different countries and things like that. Just generally speaking, how are you thinking about those businesses going to 2027?

Róbert Wessman
Chairman, Alvotech

Yeah, I think what we are seeing is that conversion with Humira to biosimilars is still ongoing in U.S. I think it has fully matured in Europe. So, we expect it to continue the conversion from the brand. Teva has been doing, as I mentioned, outstanding job in U.S. to gain not only market share, but also taking a piece of what is being converted. So, the order book for Humira is very strong. Same, I would say, applies to Stelara. So, we will see moderate growth year on year on both products from 2026, 2027. On top of that, we have Simponi in Europe, where, as I said, a very strong position in Germany, Spain, U.K., and even France. Around 25% of the market has been converted by Advanz Pharma, our partner, and that will only continue to grow, so growing into 2027.

I would then say the opportunity with Simponi into U.S. is a great one, and looking very much forward to that. Then, of course, low-dose Eylea. Amgen has been alone in the market, have been very conservative on discounting, so the market is still not eroded, if you will. So, in that one, we had a settlement with Regeneron, and so we have a clear path to launch now once we get approval.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. I think we have one minute left, so maybe just remind us of your cash and runway, et cetera.

Róbert Wessman
Chairman, Alvotech

Yeah, the company, we raised funds kind of late mid-year, if you will. We took on board 160 million new equity, if you will. Overall, what was reflected in the third quarter, we had a lot of draw on working capital.

Just based on the inventory build, if you will, both raw material and drug substance and finished products. Overall, we have said we want to see being cash positive from operation in the fourth quarter, and that's kind of where the guidance stop. We are going to guide for the company, and most likely when we announce the fourth quarter result. We will then guide more towards cash and the operation. But we should see a strong growth year-on-year, and we are all excited about the business.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Perfect. Well, I think that's all the time that we have today. Thanks for hanging out with us, and it's great to see you. Have a great conference.

Róbert Wessman
Chairman, Alvotech

Okay.

Dennis Ding
Biotech and Spec Pharma Analyst, Jefferies

Thank you.

Róbert Wessman
Chairman, Alvotech

Thank you so much.

Balaji Prasad
Chief Strategy Officer, Alvotech

Thank you.